The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hefeneider, S. H.
Right arrow Articles by Gillis, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hefeneider, S. H.
Right arrow Articles by Gillis, S.

The Journal of Immunology, Vol 130, Issue 1 222-227, Copyright © 1983 by American Association of Immunologists

ARTICLES

In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells

SH Hefeneider, PJ Conlon, CS Henney and S Gillis

Interleukin 2 (IL 2) is a T cell growth factor that has been shown to modulate several in vitro immune responses. Produced by T cells, the lymphokine has been highly purified and used in a series of in vivo studies to examine the effect of IL 2 on murine cytotoxic T cell (CTL) and natural killer (NK) cell reactivity. By employing an immunization protocol known to generate CTL activity against allogeneic tumors, in vivo administration of highly purified IL 2, either in concert, with or 2 days after, tumor administration, resulted in an augmented CTL response as compared to effector cells harvested from untreated, alloimmunized control animals. Characterization of the effector cells responsible for the augmented cytolytic activity showed them to be of the T cell lineage and to be specific for the appropriate immunizing tumor cell. Furthermore, we were able to demonstrate that administration of purified IL 2 to naive, non-antigen-challenged recipients resulted in substantial potentiation of NK cell activity. The augmented cytolytic reactivity was mediated by NK cells as evidenced by effector cell lysis of NK-susceptible but not NK- insusceptible tumor targets. The results of these studies suggest IL 2 functions in vivo as an immune response regulator and may have a beneficial effect as an in vivo immunopotentiator.


This article has been cited by other articles:


Home page
 J. Immunol.Home page
B. R. Lauwerys, N. Garot, J.-C. Renauld, and F. A. Houssiau
Cytokine Production and Killer Activity of NK/T-NK Cells Derived with IL-2, IL-15, or the Combination of IL-12 and IL-18
J. Immunol., August 15, 2000; 165(4): 1847 - 1853.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
K. Shimizu, R. C. Fields, M. Giedlin, and J. J. Mule
Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines
PNAS, March 2, 1999; 96(5): 2268 - 2273.
[Abstract] [Full Text] [PDF]

Home page
 ScienceHome page
S. Rosenberg, E. Grimm, M McGrogan, M Doyle, E Kawasaki, K Koths, and D. Mark
Biological activity of recombinant human interleukin-2 produced in Escherichia coli
Science, March 30, 1984; 223(4643): 1412 - 1414.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1983 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1983 by The American Association of Immunologists, Inc. All rights reserved.